Here’s why H1 results could boost the AstraZeneca share price

The AstraZeneca share price has been a success story in the past five years. With H1 results due, can it keep going?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE: AZN) share price has done well in 2024, and it’s up 80% in five years.

So why, a day before H1 results are due on 25 July, do I think we might still be at the start of a bull run that could go on for a decade or more?

Valuation

The valuation, to be fair, doesn’t exactly make the stock look screaming cheap. The shares are trading at around 35 times last year’s earnings. And even with earnings growth on the cards, we’d still be looking at a price-to-earnings (P/E) ratio of 28 for the current year. That’s around twice the long-term FTSE 100 average.

And it doesn’t look like we’re going to get rich on the AstraZeneca dividend. Not with a forecast yield of just 1.8%. But that P/E looks low compared to the valuations of some industry peers. Most of those are listed in the US though, where stocks are typically valued on higher multiples.

Still, forecasts would drop the P/E to around 20 by the end of 2026, less than two years away. If the earnings growth trajectory can continue as it’s doing beyond that, the shares could soon look too cheap.

Cash and debt

AstraZeneca’s been on a decade-long programme of building up its drugs pipeline, which takes a huge investment.

And that can saddle a company with a lot of debt. At the end of Q1 (31 March), net debt stood at $26.4bn (£20.5bn). That’s maybe not much for a company with a £190bn market-cap and total 2023 revenue of $45.8bn (£35.5bn).

But I do like what I see when I look at cash flow and debt forecasts. They show free cash flow rising by 55% between 2023 and 2026. And they suggest net debt could drop by 67% in the same timescale.

Pipeline delivering

When Pascal Soriot took the helm in 2012, the company was in a bad way. Blockbuster patents were expiring and generic manufacturers were making all the money.

It was always going to be a decade-plus job to get the research machine back into motion.

At Q1 time, Soriot said: “Our strong pipeline momentum continued and already this year we announced positive trial results for Imfinzi and Tagrisso that were unprecedented in lung cancer […]  We are also looking forward to seeing the results of several other important trials throughout the year.”

Pipeline back to speed? Looks like job done.

What next?

I don’t expect anything dramatic from the H1 figures, but just reiterating full-year guidance might be enough to boost the shares further.

For the long term? Drugs results have been good so far. But it might only take one or two costly failures to drag the profit outlook back down again.

On valuation, I see AstraZeneca as cheap compared to the industry and I think we could be in for good spell. But others will rate it as expensive compared to the FTSE 100. Either way, I’m looking forward to the update.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

This has to be one of the best UK stocks to buy, IMO! Here’s what the charts say

UK stocks are often considered undervalued, but very few appear to come close to this one. Dr James Fox explains…

Read more »

Investing Articles

Forecast: in 12 months, the Barclays share price could be…

The Barclays share price has surged over the past 12 months, but where will it go next? Dr James Fox…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

1 top stock offering incredible value right now!

After its recent decline, this high-quality tech share benefitting from artificial intelligence is trading more like a value stock.

Read more »

The Troat Inn on River Cherwell in Oxford. England
Investing Articles

Down 21% in 6 months! Should I buy the dip in this FTSE 250 stock?

Ben McPoland is wondering whether he should add struggling FTSE 250 share JD Wetherspoon to his Stocks and Shares ISA…

Read more »

Investing Articles

As the ISA deadline looms, here are 2 dividend-paying stocks I have been loading up on

With the opportunity to invest up to £20,000 in an ISA available, Andrew Mackie looks at two of his favourite…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

Here’s how Bitcoin could help an investor earn a £10,000 monthly passive income

Millions of Britons invest in stocks and shares in order to earn a passive income. Here, Dr James Fox explains…

Read more »

Investing Articles

$500 or $100: how much is Tesla stock really worth in 2025?

Tesla stock has fallen from $488 to $249 in the space of a few months. Is there value on offer…

Read more »

Dividend Shares

Fully using the £20k ISA allowance could make this much passive income

Jon Smith explains how much passive income could be made over time if an investor focused purely on building up…

Read more »